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Abstract:  Modern  humans  have  evolved  with  a  staple  source  of  preformed 
docosahexaenoic acid (DHA) in the diet. An important turning point in human evolution 
was the discovery of high-quality, easily digested nutrients from coastal seafood and inland 
freshwater  sources.  Multi-generational  exploitation  of  seafood  by  shore-based  dwellers 
coincided  with  the  rapid  expansion  of  grey  matter  in  the  cerebral  cortex,  which 
characterizes the modern human brain. The DHA molecule has unique structural properties 
that appear to provide optimal conditions for a wide range of cell membrane functions. 
This  has  particular  implications  for  grey  matter,  which  is  membrane-rich  tissue.  An 
important  metabolic  role  for  DHA  has  recently  been  identified  as  the  precursor  for 
resolvins and protectins. The rudimentary source of DHA is marine algae; therefore it is 
found concentrated in fish and marine oils. Unlike the photosynthetic cells in algae and 
higher  plants,  mammalian  cells  lack  the  specific  enzymes  required  for  the  de  novo 
synthesis of alpha-linolenic acid (ALA), the precursor for all omega-3 fatty acid syntheses. 
Endogenous synthesis of DHA from ALA in humans is much lower and more limited than 
previously  assumed. The excessive  consumption of omega-6  fatty acids in the modern 
Western diet further displaces DHA from membrane phospholipids. An emerging body of 
research is exploring a unique role for DHA in neurodevelopment and the prevention of 
neuropsychiatric and neurodegenerative disorders. DHA is increasingly being added back 
into the food supply as fish oil or algal oil supplementation.  
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1. Diet and the Evolution of the Large Human Brain 
A new picture is emerging which places nutrition, and docosahexaenoic acid (DHA) in particular, in 
an integral role in the evolution of human intelligence. The creation of a new database of the fossil 
record, which catalogues fossils at the level of individual collections, has been analyzed to demonstrate 
that a turning point in human evolution coincides with the inclusion of seafood in the diet [1,2]. Using 
stable isotope values of the bone collagen from human remains, it is possible to estimate the proportion 
of protein obtained in the diet from aquatic versus terrestrial sources in the 10 years prior to death. 
Further, the isotopes can distinguish between protein from freshwater wetlands and marine coasts. 
Richards et al. [2] analyzed bone specimens that had lived in the regions now known as Britain, Russia 
and the Czech Republic during the Mid-Upper Paleolithic period with published carbon isotope values 
from five Neanderthal specimens, that were dated from an earlier time and that had lived in similar 
geographic regions.  
The  late  archaic  humans  (Neanderthals)  sourced  protein  predominantly  from  the  red  meat  of 
wolves, large felids and hyenas. There was no evidence of fresh water aquatic species or marine 
sources  of  protein  in  the  bone  collagen  of  the  Neanderthal  samples.  In  striking  contrast,  seafood 
consumption was a ―staple‖ of the diet of the early modern humans (Mid-Upper Paleolithic period). 
Depending upon geographical region, freshwater or marine sources of protein constituted between  
10–50%  of  the  diet  for  the  early  modern  humans.  Freshwater  sources  occurred  along  rivers  and 
included fish and/or water fowl and marine sources were coastal and included fish, shellfish and small 
slow-moving animals such as turtles/tortoises. When the radio isotope values were aggregated, the 
between-group difference in the values was statistically significant (p = 0.005).  
Interestingly, the exploitation of food from aquatic and marine sources coincided with a rise in a 
more elaborate enrichment in material culture, such as personal ornamentation, decoration of burials, 
pottery figurines and knotted textiles. Richards et al. [2] concluded that the inclusion of seafood is 
likely to have ―…rendered humans more resilient to natural pressures and the increasingly packed 
social environments of Late Pleistocene Europe‖.  
Crawford, Broadhurst and Cunnane et al. [3–6] move the argument forward by linking diet with 
brain size; specifically, the expansion of the diet to include seafood with the expansion of grey matter 
in the cerebral cortex. They note that over 3 million years of evolution had little effect on the brain 
capacity of Australopithecus spp. Conversely, brain capacity doubled in the million years between 
Homo  erectus  and  Homo  sapiens.  In  fact,  they  observed  that  encephalisation  growth  rate  was 
exponential in the past 200,000 years [5].  
Broadhust  et  al.  [3]  provide  compelling  evidence  that  the  discovery  and  subsequent  
multi-generational exploitation of seafood coincides with the rapid expansion of the cerebral cortex 
that  is  unique  to  modern  humans.  The  brains  of  42  modern  mammalian  species  were  studied  by 
Crawford et al. [5] and found to be similar in brain chemistry, particularly in the predominant use of Nutrients 2011, 3  
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DHA in the membrane-rich neural tissues at synapses and in the retina. They found that Homo sapiens 
are characterized by the disproportionately large brain size in proportion to the body. In every other 
land-based mammalian species they studied, brain size decreased logarithmically with increases in 
body size.  
Crawford et al. [5,6] argue that these findings are explained if the relative rate of brain to body 
growth was rate-limited by the inadequate biosynthesis of DHA in the liver. Support for this theory is 
given by evidence that in the absence of a significant source of preformed DHA in the food chain, 
land-based mammalian brains did not substitute the 22-carbon omega-6 fatty acid, docosapentaenoic 
acid (DPA 22:5n-6), despite its abundance. Thus, they argue, it was brain size that was sacrificed, not 
the degree of unsaturation in the phospholipid membranes.  
By comparison with early humans, the gross expansion of grey matter and enlarged cerebral cortex 
coincides  with  increased  intelligence  in  modern  humans.  Perhaps  the  most  widely  held  theory  of 
evolution explains the growth of human intelligence as due to an interaction between tool making, 
language development and brain expansion. However, Cunnane and Crawford [7] argue that brain 
expansion due to the discovery of a convenient source of high-quality dietary nutrients is likely to have 
preceded both the expansion of the grey matter and the development of language and tools making.  
Shore-based dwellers had relatively easy access to high-quality, nutrient-dense diets. They departed 
from traditional plant and occasional meat diets by providing a constant supply of fatty acids and 
proteins that were easily digested. Seafood did not require extensive preparation or grinding, as did 
plant tubers and red meat. Shore-based foods were readily available and reduced reliance on hunting, 
perhaps to the point where hunting became optional. All people, young and old, could feed themselves, 
which may have freed up time for other pursuits such as the development of tools and elaborations in 
decorations  and  textiles,  which  over  the  generations  perhaps  preceded  the  cultivation  of  art  and 
language [7].  
2. Dietary Fatty Acids  
Most fatty acids found naturally in the diet consist of long, straight hydrocarbon chains with a 
carboxylic acid group at one end and usually a methyl group at the terminal end. The number of carbon 
atoms is usually even; those in animal fats and vegetable oils are usually between 12 and 22 [8]. They 
are classified according to the number of carbon atoms in their side chains and are thus ―short‖ (<8), 
―medium‖ (8–12), ―long‖ (14–18) or ―longer‖ or ―very long‖ (≥20) chain fatty acids. They are further 
classified according to the degree of unsaturation (double-bonds) between the carbon atoms in the side 
chain. A short-hand way of denoting them is to provide the number of carbon atoms (C), followed by a 
colon and the number of double bonds. These physical characteristics have profound effects on their 
functional properties. 
Saturated fatty acids are linear carboxylic acids containing only single bonds and are solid at room 
temperature. An example is myristic acid from butter, which has 14C and no double-bonds (14:0). 
Monounsaturated fatty acids are long-chain carboxylic acids with one double-bond. The most abundant 
monounsaturated fatty acid found in nature is oleic acid, as found in olive oil, which has 18C and one 
double-bond, on the 9th carbon atom (18:1).  Nutrients 2011, 3  
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The double-bonds in unsaturated fatty acids found in nature are generally in the cis configuration. 
That  is,  the  two  hydrogen  atoms  on  either  side  of  the  double  bond  are  on  the  same  side  of  the 
molecule. The cis double-bond is significant as it introduces a bend or ―kink‖ into the fatty acid side 
chain. Trans double bonds, found rarely in nature but prolifically in processed foods in the Western 
diet through the partial-hydrogenation of unsaturated fatty acids, effectively straightens the side chains 
so that they stack closely together in a linear formation similar to the packing of saturated fatty acids. 
Trans fats are also solid at room temperature while the equivalent molecule in the cis formation is 
liquid at room temperature.  
Polyunsaturated fatty acids (PUFAs) include long and very-long chain carboxylic acids containing 
two or more double-bonds, most commonly in the cis configuration, introducing multiple kinks that 
facilitate folding configurations of the hydrocarbon chain. The two major families of polyunsaturated 
fatty acids are the omega-6 fatty acids with its 18C precursor, linoleic acid (LA), and the omega-3 fatty 
acids, with its 18C precursor, alpha-linolenic acid (ALA). These families are named after the position 
of the first double bond from the ―omega‖ or terminal methyl end of the molecule. Omega is the last 
letter in the Greek alphabet and is used to indicate the reversal in the direction of counting [9]. This 
omega nomenclature is widely used in fatty acid chemistry and is frequently denoted by the symbol  
n minus, such as ―n-3‖ or ―n-6‖.  
The omega-3 fatty acids are generally more highly unsaturated than their omega-6 counterparts. 
Linoleic acid (LA or 18:2 n-6) is rich in vegetable seed oils such as sunflower seed oil and has 18C 
and two double-bonds. Alpha-linolenic acid (ALA or 18:3 n-3) rich in flaxseed oil and green, leafy 
vegetables, has 18C with three double-bonds. The 18C fatty acids are precursors for longer-chain fatty 
acids. However, the longer-chain metabolites are also found in nature in their preformed state. They 
include  the  omega-6  arachidonic  acid  (AA  or  20:4n-6),  and  the  omega-3  eicosapentaenoic  acid  
(EPA or 20:5n-3) and docosahexaenoic acid (DHA or 22:6n-3).  
Arachidonic acid (AA) is found in the flesh of lean red meat and chicken, in egg yolks and human 
milk  [10].  AA  (20:4n-6)  has  20C  with  four  double-bonds  [8].  EPA  and  DHA  are  synthesized  in 
abundance  by  marine  algae  and  found  concentrated  in  fish  and  marine  oils,  particularly  the  oil 
compartments of cold water fish. In non-fish eaters, eggs are an important source of DHA and dairy 
products provide some EPA [11]. In a study of 14,422 middle-aged English men and women [11], 
―soups  and  sauces‖  were  a  major  source  of  DHA  and  ―spreading  fats‖  of  EPA,  for  vegetarians  
(who  exclude  meat  from  their  diet)  although  no  further  specific  information  was  provided. 
Interestingly, they found that while vegans (who exclude meat, eggs and dairy from their diet) had no 
dietary intake of preformed DHA, their intakes of EPA were similar to those of vegetarians, as both 
men and women from both dietary groups sourced EPA predominantly from ―spreading fats‖ with the 
exception of vegan women, who sourced EPA predominately from ―soups and sauces‖.  
The  EPA  molecule  has  20C,  but  where  AA  has  four  double-bonds,  EPA  (20:5n-3)  has  five  
double-bonds; DHA (22:6n-3) has 22C and six double-bonds. Thus, of these fatty acid nutrients, DHA 
has the longest side-chain and highest degree of unsaturation. This property appears to confer unique 
structural and functional properties to cell membrane phospholipids, particularly those in the retina and 
the neuronal synapses in the brain.  Nutrients 2011, 3  
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3. Nutritional Essentiality 
Linoleic  (n-6)  and  linolenic  (n-3)  acids  are  synthesized  from  oleic  acid  in  plant  tissue  by  the 
insertion of double-bonds between the existing double-bond and the methyl (omega) end of the side 
chain [12]. Animal cells lack these specific enzymes (delta-12 and delta-15 desaturase) and as such 
rely solely on obtaining these nutrients from the diet. Because they are required for vital biological 
functions  and  the  body  shows  deficiency  symptoms  when  intake  is  inadequate,  linoleic  acid  and 
linolenic acid meet the conditions of nutritional essentiality [13].  
Linoleic acid (LA) and alpha-linolenic acids (ALA) are the two traditionally recognized essential 
fatty acids. Linoleic acid (LA) was the first to achieve nutritional essentiality status, some 80 years  
ago [14]. It is required for the normal function of the stratum corneum ceramides, which prevent  
trans-epidermal  water  loss.  Dietary  deficiency  is  characterized  by  severe  scaly  dermatosis  that  is 
reversible by administration of LA but not ALA [15]. Deficiency is not common in the Western diet, 
which is characterized by excess intake of LA.  
The  extent  and  consequences  of  dietary  omega-3  fatty  acid  deficiency  are  not  yet  completely 
understood. Suboptimal intakes of ALA, EPA and DHA, characteristic of the Western diet, have been 
correlated with many ―Western lifestyle‖ diseases, particularly coronary heart disease [16]. The first 
instance of ALA deficiency was recorded in 1982 and describes a case of a 6 year old girl that had lost 
part of her intestine to surgery following a gunshot wound. She was maintained on total parental 
nutrition which contained safflower oil, rich in LA but very little ALA (69% LA, <1% ALA). After 
five months she suffered ―numbness, paresthesia, weakness, inability to walk, pain in the legs, and 
blurring of vision‖ [17]. When the oil in the nutritional formula was changed to soybean oil, which 
includes ALA (54% LA, 7% ALA), the neurological disturbances were reversed. Holman et al. [17] 
determined  the  minimum  dose  required  to  prevent  deficiency  symptoms  was  0.5–0.6%  ALA  to  
total energy.  
Subsequent studies by Bjerve et al. [18] in institutionalized elderly patients fed entirely with gastric 
tubes a formula based on corn oil (61% LA, 1% ALA) could not assess nervous system pathology due 
to the age of the patients. However, patients presented with light, flakey skin dermatitis together with 
low blood phospholipid levels of EPA and DHA. When ALA was included in the formula, EPA and 
DHA  levels  were  normalized  in  blood  phospholipids  and  the  cutaneous  symptoms  were  resolved 
within four weeks. Bjerve et al. [18] observed that conversions from ALA to EPA and DHA appear to 
be increased in adults with frank deficiency. However, they recommend that adults require a minimal 
daily intake of 0.2–0.3% ALA and 0.1–0.2% EPA + DHA.  
By the end of the decade, and after much intense research, the 1989 NATO Advanced Research 
Workshop on dietary n-3 and n-6 fatty acids on biological effects and nutritional essentiality, agreed 
by consensus that n-3 fatty acids generally: (1) have anti-inflammatory properties; (2) lower serum 
triglycerides  and  cholesterol;  and  (3)  decrease  thrombosis  and  platelet  aggregation.  Therefore 
administration was recommended as beneficial in cardiovascular disease, hypertension and rheumatoid 
arthritis [19]. Since then, however, there has been a wealth of evidence to support the notion that the 
omega-3 fatty acids are not bioequivalent and that the longer chain EPA and DHA are much more 
important than their precursor ALA [20,21].  Nutrients 2011, 3  
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ALA is metabolized to EPA, currently thought to occur predominately in liver cells, by sequential 
desaturation  and  elongation:  delta-6  desaturase,  chain  elongation  and  delta-5  desaturase.  EPA  is 
elongated to DPAn-3 (22:5n-3 or docosapentaenoic acid). DPAn-3 is then metabolized to DHA in 
several relatively more complex steps. Firstly it is elongated then desaturated via delta-6 desaturase to 
form the intermediate molecule 24:6n-3. It must then be taken into the peroxisomes to undergo limited 
β-oxidation to remove two carbon atoms in a process known as retro-conversion or the ―Sprecher‖ 
pathway [12]. Interestingly, microalgae seem to be more efficient at synthesizing DHA by bypassing 
the last three steps and simply metabolizing DHA in one step from DPA with delta 4 desaturase [12].  
These  conversions  have  long  been  assumed  to  be  rate-limited  by  hepatic  delta-6  desaturase, 
although delta-6 desaturase has also been found in the brain and skeletal muscles, suggesting the 
possibility  of  alternative  pathways  for  the  maintenance  of  EPA  and  DHA  [22].  While  brain  
delta-6 desaturase is demonstratively active in the neonate, however, it appears to rapidly decline with 
age. Cook et al. [23] report on animal studies that have shown the peak brain ∆6 desaturase capacity 
corresponds with the period of the most rapid brain growth, 4–5 days after birth.  
Conversions through to DHA in adults have been found to be very low. When stable isotope-labeled 
ALA was given to a sample healthy young male volunteers in the UK that did not take fish oil or 
regularly eat fish, there was very little conversion right through to DHA (EPA 7.9%, DPA 8.1% and 
DHA 0–0.04%) [24]. These findings were consistent with those from a population of pregnant women 
that found supplementation with ALA significantly increased maternal and neonatal EPA and DPA  
but  not  DHA  [25].  However,  results  from  a  study  in  non-pregnant  females  found  approximately  
10% conversion through to DHA (EPA 21%, DPA 6% and DHA 9%) [26]. 
Furthermore, in vegetarians ALA supplementation was demonstrated to increase the proportion of 
EPA but not DHA [27]. When given as preformed DHA, however, there are consistent and dramatic 
increases  in  DHA  in  phospholipids.  For  instance,  when  900  mg  per  day  of  algal-DHA  was 
administered to vegetarians for 8 weeks there were significant increase in the proportion of DHA in 
phospholipids,  from  2.8%  to  7.3%  [28].  Similarly,  supplementation  of  200  mg  DHA  per  day  for 
3 months was shown to increase serum phospholipids by 50% in vegetarians [27]. It would thus appear 
that only supplementation with preformed DHA reliably increases tissue DHA [29,30].  
Because ALA itself is not incorporated into the phospholipids of cell membranes in appreciable 
amounts and there is now clear evidence that there is limited biosynthesis to DHA, the assumption that 
ALA is the essential omega-3 nutrient has recently been challenged [30]. It has been proposed that 
DHA be considered at least ―conditionally essential‖ [31]. Indeed, there is evidence that small amounts 
of only EPA and DHA can reverse omega-3 deficiency [20]. While EPA is required for eicosanoid 
synthesis,  the  widespread  presence  and  preferential  retention  of  cell  membrane  phospholipids  for 
DHA, particularly in the brain, indicates that DHA is the essential omega 3 fatty acid.  
Membrane-rich nervous tissue, such as that found in the grey matter, has a particular affinity for 
DHA.  While  the  omega-6  fatty  acid,  DPAn-6,  and  DHA  are  both  22C  molecules,  DHA  has  the 
additional double-bond at the methyl end of its hydrocarbon side chain. This may suggest that it is this 
additional double-bond on the 22C molecule appears to be preferentially required by cell membrane 
phospholipids in the CNS. An alternative theory, however, is that the CNS requires 22C molecules but 
because neurons themselves do not synthesize them, they rely on an external source. A major source is 
from neighboring support cells called astrocytes.  Nutrients 2011, 3  
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When astrocytes are incubated with radio labeled ALA, the main metabolic product is DHA, but 
when incubated with LA, the predominant product is AA, rather than DPA [32]. Thus, AA and DHA 
are the two fatty acids predominately secreted by astrocytes. Even during DHA deficiency, DPA only 
partially replaces DHA, with AA and docosatetraenoic acid (22:4n-6) also increased. Furthermore, 
incubated astrocytes produced about 20 times more DHA than DPA, and secreted 45 times more DHA 
than DPA into the extracellular fluid. This metabolic activity of astrocytes may explain why brain 
DHA levels are much higher than DPA, despite the relative abundance of n-6 fatty acids in the diet. 
This  astrocyte  evidence  indicates  a  highly  selective  metabolic  preference  for  DHA  synthesis  by 
astrocytes that cannot be completely functionally replaced by DPAn-6. Thus, it has been argued as 
highly likely that this CNS selective requirement for the 22C molecule with the additional double-bond 
(DHA) is the primary reason that the omega 3 fatty acids are considered nutritionally essential [32].  
The current US Institute of Medicine recommendation for ALA intake is 1.6 g/day for men and  
1.1 g/day for women, 10% of which can be consumed as EPA + DHA [33]. This proportion represents 
the current mean intake of EPA + DHA in the American diet, approximately 100 mg per day. In most 
Western countries, the current recommendations for the prevention of coronary heart disease from 
health bodies are approximately 500 mg per day from EPA + DHA, the equivalent of two oily fish 
meals per week [33]. When nutrients are consumed, either as fortified food or supplements, for the 
purpose of the prevention and/or treatment of disease, the nutrients are also increasingly known as 
―nutraceuticals‖ [34]. The nutraceutical dosages of EPA and DHA are generally much higher than their 
physiological or basal levels, which remain largely undetermined. During pregnancy, some recommend 
200 mg/day DHA, while intakes up to 3 g per day of DHA have been shown to be safe [35,36].  
France is the only country where recommendations specifically for DHA are provided by health 
bodies at 120 mg for men and 100 mg for women per day. A recent survey of 4884 French men and 
women found that on average this target was far exceeded by estimated intakes of 273 mg/day for men 
and 226 mg/day for women [37]. In addition, the total long chain omega 3 fatty acids (EPA + DHA) 
intakes in France are in line with the recommended nutraceutical doses for the prevention of heart 
disease, at an estimated 497 mg/day for men and 400 mg/day in women. The French estimates for 
preformed DHA (250 mg/day), predominately from seafood, are much higher than estimates from 
other Western countries, such as 70 mg/day in the US, 90 mg/day in Australia, and 170 mg/day in 
Germany.  These  observations  may  in  part  contribute  towards  the  ―French  Paradox‖,  the  lower 
incidence of heart disease despite the diet rich in saturated fatty acids [29].  
It  is  important  to  note that  it  is  the  fatty  acid  proportions  in  the  phospholipids  of  plasma  and 
erythrocyte cell membranes that have widely and routinely been used as biomarkers to reflect the 
omega-3 status of body organs, such as the heart and the brain. This is the case in the large volume of 
literature demonstrating the beneficial effects of omega-3 fatty acids in coronary heart disease, and 
more  recently  the  emerging  literature  regarding  their  effects  in  neuropsychiatric  disorders.  For 
instance, the work of Harris et al. [38] and von Schacky [39] have established that the most reliable 
fatty  acid  indicator  for  risk  of  coronary  heart  disease  is  EPA  +  DHA  in  erythrocyte  membrane 
phospholipids. Further, Harris et al. [38] demonstrated that erythrocyte DHA phospholipids correlated 
highly with cardiac DHA phospholipids (r = 0.84, p = 0.01). Blood biomarkers for DHA, in both 
erythrocyte and plasma phospholipids, are considered highly reliable indicators of the DHA status of 
both cardiac and brain tissue [40].  Nutrients 2011, 3  
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Vegetarian and vegan diets have been associated with markedly lower plasma phospholipid DHA 
fatty  acid  fractions  [41].  In  a  recent  large  cross  sectional  study  of  middle-aged  English  men  and 
women aged 39–78 years that do not consume fish oil supplements, Welch et al. [11] analyzed 7-day 
food diaries. The blood phospholipids fatty acid profiles of a subsample were also analyzed. The male 
sample  is  reported  here  although  values  are  also  available  for  women.  The  means  and  standard 
deviations of the estimated intakes of DHA in grams per day for male fish-eaters (n = 5952) was  
0.16 ±  0.22 g/day, meat-eaters (n = 966) was 0.02 ±  0.02 g/day, vegetarians (n = 96) was 0.0007 ±  0.004 
and vegans (n = 12) was zero. It should be noted, however, that EPA intakes were present in vegans  
at 0.01 ±  0.001 g/day in men and 0.002 ±  0.008 in women, and was overall in a similar range to those 
of vegetarians. 
Although  vegans  had  zero  intake  of  preformed  DHA,  it  was  nevertheless  present  in  blood 
phospholipids. In a subgroup of this sample, the means and standard deviations of the DHA in the 
blood phospholipids were measured in µmol/L: fish-eaters (n = 2257) were 239.7 ±  106.2, meat-eaters 
(n = 359) were 215.6 ±  96.4, vegetarians (n = 25) were 222.2 ±  138.4 and vegans (n = 5) were  
195.0 ±  58.8. Welch et al. [11] calculated the ratio of dietary precursor (ALA) to product (EPA + DHA). 
This  ratio  for  fish-eaters  (n  =  2257)  was  0.093  ±   0.001  µ mol/L,  meat-eaters  (n  =  359)  was  
0.101 ±  0.004, vegetarians (n = 25) was 0.108 ±  0.012 and vegans (n = 5) was 0.199 ±  0.027. Thus the 
precursor/product ratio in vegans was twice that of fish-eaters. This finding suggests basal conversions 
from ALA to DHA that may be up-regulated by the absence of—and down-regulated by the presence 
of—dietary preformed DHA. 
4. Cell Membrane Phospholipids 
Animal cell membranes consist of a thin bilayer of phospholipids that is continuous over the whole 
cell. Critical functions of the cell membrane may be grouped (1) maintenance of membrane fluidity, 
(2) ligand binding to receptors, (3) cell signaling and gene expression, (4) eicosanoid and docosanoid 
synthesis [42]. The predominate polyunsaturated fatty acids incorporated into cellular membranes are 
the  longer-chain  polyunsaturated  fatty  acids;  AA,  dihomogammalinolenic  acid  (dGLA),  EPA  and 
DHA [43]. The types and distribution of fatty acids within the cell membrane phospholipids vary 
according to the cell type [44].  
Experimental  and  evolutionary  evidence  supports  the  notion  of  a  unique  role  for  DHA  in  cell 
membranes. Salem et al. [45] report that the loss of a single double bond from the hydrocarbon chain 
significantly alters the properties of the membrane. Computerized three-dimensional energy-minimized 
structures of DHA (22:6 n-3) compared with DPA (22:5 n-6) demonstrated that the final double-bond 
in DHA (not present in DPA n-6) enables the molecule to take a slightly spiral (helical) structure [5]. 
This property is thought to provide the membrane with a certain molecular order or ―fluidity‖ that may 
be required for optimal functioning [46].  
Recent  molecular  dynamic  modeling  of  phospholipids  bilayers  have  consistently  demonstrated 
increased membrane flexibility when DHA is present compared with other fatty acids. Feller et al. [47] 
demonstrated  over  100  alternative  likely  configurations  for  DHA  in  phospholipids.  In  fluid  the 
molecule is constantly changing, when extended it takes a twisted, helical configuration, but often 
takes a ―hairpin‖ shape where the terminus end is back-folded close to the bilayer. These properties Nutrients 2011, 3  
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were shown in molecular dynamic studies to result in more highly flexible membranes which were less 
sensitive to mechanical stress than saturated fatty acids [48]. Other modeling studies have shown that 
the  lower  melting  point  for  the  less  unsaturated  arachidonic  acid  was  associated  with  increased 
disorder in fluid compared with DHA [49]. Unsaturated chains have been associated with thinner, 
more  permeable membranes  with increased  water  permeation when  compared with saturated fatty 
acids [50]. Huber et al. [48] speculate that the long highly unsaturated chain of DHA in membrane 
phospholipids may facilitate solvation in hydrophobic areas for the benefit of G-coupled membrane 
proteins such as rhodopsin. 
These recent advances in understanding the influence of the highly unsaturated DHA molecule in 
the membrane phospholipids has fuelled speculation that it may work as a metabolic ―pacemaker‖ for 
cells,  and  perhaps  influence  the  metabolism  of  the  whole  organism  via  an  impact  on  the  basal 
metabolic rate [51]. This theory was tested by Turner et al. [52], who demonstrated a positive linear 
relationship between the high molecular activity of the enzyme Na
+K
+ATPase (the sodium-potassium 
pump) and membrane concentration of DHA in the surrounding phospholipids in brain, heart, and 
kidney tissue of samples from both mammals and birds. Further, the highest concentration of DHA 
was found in the mammalian brain as was the highest activity rate of the pump. This is significant as 
the sodium-potassium pump accounts for some 20% of the basal metabolic rate but approximately 
60% of the energy utilization in the brain.  
Brenna and Diau [53] found that cerebral DHA levels are highest in high energy tissue. They 
demonstrated a direct linear relationship (r
2 = 0.68, p = 0.003) between DHA levels in brain tissue and 
local cerebral metabolic rate of glucose uptake into cells. As levels of cellular metabolism increase, so 
does its byproduct, oxidative stress. Brenna and Diau suggest these observations are consistent with a 
critical structural role for DHA in the cell membrane and perhaps also a metabolic role for DHA in the 
regulation  of  oxidative  stress.  Together,  these  findings  may  provide  a  biochemical  basis  for  a 
beneficial role for DHA in the metabolic syndrome and also neurodegenerative disease processes.  
The physical properties of the DHA side chains in membrane phospholipids appear to influence cell 
signaling. One wide ranging mechanism may be via an influence on the G-protein coupled receptor, a 
trans-membrane  protein  which  binds  signaling  molecules  on  the  outside  of  the  cell  and  activates 
second-messengers inside the cell. G-proteins modulate sodium and potassium channels by altering the 
threshold, amplitude and duration of the action potential (electrical impulse). G-proteins are coupled 
with  α-  and  β-adrenergic,  dopaminergic,  serotonergic,  glutamate,  muscarinic,  or  acetylcholinergic 
receptors. G-proteins also modulate the activity of phospholipase A2 (PLA2), the enzyme that targets 
the polyunsaturated fatty acids in the Sn-2 position of phospholipids.  
During any threat to cell  or  local tissue homeostasis, PLA2 stimulates the phospholipid release  
of  the  20C  fatty  acids.  The  predominant  fatty  acid  released  is  arachidonic  acid  but  EPA  and  
dihommo-gamma linolenic acid (dGLA or 20:3n-6) may also be released, subject to availability. AA is 
metabolized  through  oxidation  into  extremely  potent,  short-range,  hormone-like  inflammatory 
signaling  molecules,  characterized  by  their  high  metabolic  turnover  and  collectively  known  as 
eicosanoids. Two major families of oxidation enzymes convert the 20C fatty acids into their respective 
eicosanoids: (i) cyclooxygenases (COXs) to the prostaglandins (for example, PGE2) and thromboxanes, 
and (ii) lypoxygenases (LOXs) to leukotrienes (for example, LTB4) and lipoxins. Those eicosanoids 
derived from arachidonic acid substrates are generally far more potent in terms of pro-inflammatory Nutrients 2011, 3  
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and pro-thrombotic signaling activity than those from the EPA and dGLA. For instance, PGE2 and 
LTB4 induce pro-inflammatory cytokine production and secretion, particularly interleukins IL-6 and 
IL-1β and tumor necrosis factor (TNF) [54]. A recently identified mechanism for PGE2-induced IL-6 
production is via direct activation of the nuclear transcription factor kappa B (NF-κB) [55].  
NF-κB  is  a  protein  that  resides  in  the  cytoplasm  of  immune  cells  (particularly  B  and  T 
lymphocytes). In its latent form it is bound to an inhibitory protein (IκB) but after activation by an 
inducer,  IκB  is  degraded  and  NF-κB  is  released.  It  moves  rapidly  into  the  cell  nucleus  where  it  
up-regulates the expression of the genes for many proinflammatory mediators, such as the cytokines 
IL-2, IL-6, and IL-8. These events mediate a cascade of inflammatory processes both locally and if 
produced in sufficient quantities, systemically. NF-κB activation is extremely sensitive to oxidative 
stress. For instance, raised levels of reactive oxygen species (ROS), which are natural bi-products of 
metabolic activity, activate NF-κB through the degradation of IκB. This mechanism can be inhibited 
by antioxidants [56] and DHA. 
DHA is a potent regulator of NF-κB via multiple mechanisms [57]. DHA itself was shown to 
directly inhibit NF-κB activation [58]. Mice macrophage cells that were stimulated with the bacteria 
LPS  and  interferon,  increased  nitric  oxide  (NO)  production.  Pre-treatment  with  various 
polyunsaturated fatty acids demonstrated that DHA had a marked dose-dependent inhibitory effect on 
NO  production.  Further,  DHA  prevented  the  activation  of  NF-κB  by  up-regulating  intracellular 
glutathione to a level high enough to effectively balance the oxidative stress. It is interesting to note 
that  these  anti-inflammatory  effects  of  DHA  are  mediated  via  increasing  the  availability  of  
intracellular antioxidants.  
Indirect mechanisms for DHA include mediation of anti-inflammatory effects via its oxidation to 
potent  signaling  molecules,  resolvins  and  protectins,  collectively  known  as  docosanoids.  During 
conditions  of  tissue  stress,  both  EPA  and  DHA  may  be  released  from  phospholipids  to  undergo 
conversions to ―resolution phase interaction products‖, known as resolvins [12]. Two distinct resolvin 
molecules have been identified for EPA (E1 and E2) and four for DHA (D1–D4). Oxidation occurs via 
the  LOX  enzymes.  During  local  tissue  inflammation,  cells  in  blood  vessel  walls  convert  DHA  to  
17S-HDHA via 15-LOX. The molecule is secreted from vascular cells and taken up by neighboring 
neutrophils for conversion via 5-LOX to its family of D-series resolvins. The actions of the resolvins 
are similar to those of the lipoxins, oxidized from arachidonic acid and EPA substrates, in that they 
actively promote resolution of inflammatory processes. Known anti-inflammatory mechanisms for the 
resolvins include the down-regulation of NF-κB and the removal of neutrophils from inflammatory 
sites [57].  
In addition to resolvins, DHA has recently been discovered as the precursor for a newly identified 
docosanoid called protectin, or neuroprotectin when it is found in the central nervous system. Protectin 
is synthesized by peripheral blood mononuclear cells and CD4 cells in response to oxidative stress and 
has been found in neurons, astrocytes, peripheral blood and lung tissue [12]. As the first protectin 
identified, it was designated D1 or NPD1 when found in nervous tissue [59]. NPD1 induces nerve 
regeneration,  reduce  leukocyte  infiltration  and  maintains  homeostasis  through  ageing  by  reducing  
pro-apoptotic and pro-inflammatory signaling [60]. NPDI is induced by oxidative stress and protects 
retinal  and  neuronal  cells  from  oxidative  stress-induced  apoptosis.  Many  mechanisms  have  been 
implicated, including suppression of the IL-1β induced stimulation of COX [61]. The discovery of Nutrients 2011, 3  
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NPD1  offers  new  therapeutic  opportunities  for  a  range  of  neurodegenerative  conditions,  such  as 
Alzheimer’s disease. It also provides an exciting potential for DHA in helping to delay or minimize the 
―normal‖ cognitive decline during ageing [62].  
DHA  is  also  associated  with  other  neuro-protective  factors.  Mice  fed  a  DHA-rich  diet  had 
significantly higher levels of brain-derived neurotrophic factor (BDNF) in the striatum, an area of the 
brain involved in Parkinson’s Disease [63]. Mice fed an omega-3 deficient diet for 4 weeks after 
weaning  had  reduced  levels  of  striatum  DHA  and  BDNF  compared  with  control  mice  [64].  The 
neurotrophic family of proteins, including BDNF, are integral for neurogenesis but it has also been 
suggested they continue in the long-term maintenance of the function, shape and plasticity of neurons, 
especially in high electrical areas, during ageing [65]. 
Studies aiming to demonstrate that DHA is effective in the prevention of age-related cognitive 
decline  have  so  far  shown  promising  results,  although  not  all  studies  have  been  successful  
in  demonstrating  its  efficacy.  In  485  aged  volunteers  in  the  US  with  a  memory  deficit,  
Yurko-Mauro et al. [66] demonstrated a significant improvement after 900 mg/day DHA for 24 weeks 
compared with controls on a paired-associated learning task, a visual-spatial test that was part of a 
battery of neuropsychological tests (CANTAB) (p < 0.02). Johnson et al. [67] also found significant 
improvement in verbal fluency scores (p < 0.03) with 800 mg/day DHA for 4 months compared with 
placebo in 49 ageing women in the US. In addition, memory and rate of learning were significantly 
improved when DHA was combined with lutein (12 mg/day).  
A systematic review failed to find an effect for DHA in cognitive decline during normal ageing, but 
the authors did not include a search of the psychology databases and found only one cohort study upon 
which to base their assessment [68]. A recent RCT by Dangour et al. [69] in a population of 867 aged 
healthy adults, assumed to  be at risk of age-related  cognitive decline, did not show an  effect  for  
500 mg/day DHA + 200 mg/day EPA on cognitive function after 24 months. This was due to the 
unexpected finding that the control group did not exhibit the predicted age-related cognitive decline. 
Indeed,  neither  group  exhibited  signs  of  significant  cognitive  decline  during  the  study  period. 
Therefore, a difference between the groups would have required the intervention to demonstrate a 
significant  improvement  in  cognitive  function,  rather  than  the  intended  maintenance  of  cognitive 
function, quite a different research question. Dangour et al. [70] have reflected on possible design 
issues that may confound results in large cohort prevention studies of this kind. The evidence for a 
pharmacological or nutraceutical effect of DHA in the prevention of age-related cognitive decline 
remains an emerging and promising area of research.  
5. Brain Uptake of DHA 
The brain is the most energy-demanding of all the human body organs, accounting for 2.3% of the 
total body weight but 23% of the body energy utilization in adults and 74% of the energy utilization in 
newborn term infants [7]. The brain is a lipid-dense organ, second only to adipose tissue [71]. Brain 
lipids are far more complex structurally and functionally. Indeed 60% of the dry weight of the brain 
consists of phospholipids.  
Two  important  phospholipid  subcategories,  glycerophospholipids  and  sphingolipids,  are  critical 
elements of all cellular membranes but particularly membrane-rich tissue such as grey matter [57]. Nutrients 2011, 3  
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Glycerophospholipids consist of a glycerol backbone with two fatty acid chains attached; a saturated 
fatty acid is usually found in the Sn-1 position, and an unsaturated fatty acid in the Sn-2 position. The 
Sn-3 position attaches a phosphate, bonded to a defining polar head group, such as choline, serine, 
ethanolamine or inositol [57]. In the brain, the phospholipids with the highest content of DHA are the 
ethanolamine (PE) and serine (PS) glycerophospholipids (phosphoglycerines) [5].  
Grey matter consists mostly of neurons and is 40% lipids, while white matter includes myelin and 
comprises 50–70% lipids. The distribution of unsaturated fatty acids in the glycerophospholipids of the 
brain is tissue-specific, with the white matter higher in monounsaturated fatty acids and grey matter 
higher in polyunsaturated fatty acids. In the brain, DHA is the predominant omega-3 fatty acid and AA 
the predominant omega-6 fatty acid. In grey matter, there is more DHA than AA, but in white matter 
this is reversed [57].  
In  a  brain  mapping  study  of  the  DHA  content  of  26  brain  regions  in  post-mortem  brains  of  
four-week old breast fed-baboons, the density of DHA and AA in grey matter was significantly higher 
than those in white matter regions. The density grey matter DHA was significantly variable among 
different regions of the cerebral cortex, which averaged 14% w/w DHA. The pre-centralis had the 
highest density of DHA (14.6 ±  0.9% w/w), while the temporal lobe had the least (12.2 ±  0.7% w/w). 
DHA  was  also  rich  in  the  frontal  lobe  (12.8  ±   0.6%  w/w).  In  the  white  matter  surrounding  the  
pre-centralis region, DHA density was significantly lower (5.5 % ±  0.9% w/w).The areas with the 
highest density of AA was the amygdale (13.7 ±  0.5% w/w), frontal lobe (13.6 ±  0.4% w/w) and 
temporal lobe (13.6 ±  1.2% w/w) [72].  
Interestingly, the unsaturated fatty acid composition of normal brain tissue is age-specific. The 
glycerophospholipids in the cerebral cortex of the normal ageing brain show steady increases in the 
concentration of DHA (22:6n-3) with corresponding reductions of AA (20:4n-6). Svennerholm [73] 
demonstrated, in tissue samples from 11 brains from fetal to 82 years, that the percentages of AA and 
DHA  methyl  esters  in  cerebral  cortex  ethanolamine  glycerophospholipids  was  roughly  equal  or  
1:1  (16.5%  AA  and  16.1%  DHA)  in  the  one  month  old human  infant,  but  by  the  82nd  year  the 
percentage of DHA has more than doubled and increased in proportion to AA close to approximately 
1:4 (10.3% AA and 33.9% DHA) [73].  
More recently, Carver et al. [74] studied cerebral cortex tissue from 58 human brains, whose age at 
the time of death ranged from 2–88 years. They confirmed that AA concentrations appear to decline 
with  age.  Interestingly,  they  noted  that  LA  (18:2n-6)  significantly  increased  with  age,  suggesting 
declining efficiency of the desaturase conversions. Brain samples from those younger than 18 years of 
age had declining levels of several polyunsaturated fatty acids with the notable exception of DHA, 
which  significantly  increased.  In  samples  from  those  over  18  years,  erythrocyte  fatty  acids  were 
independent predictors for cerebral cortex fatty acids. For DHA, the intercept, α = 3.419 and the 
regression coefficient, β = 0.019, which was significant at the 95% probability level (p = 0.05). Thus, 
inserting the erythrocyte levels (X) into the regression equation (Y = 3.419 − 0.019X) would predict 
DHA levels in the cerebral cortex (Y). Similarly, in those under 18, age was a significant predictor  
(α = 9.630, β = 0.203, p = 0.001) of DHA levels in the cerebral cortex.  
Neuronal  membrane  phospholipids  preferentially  retain  DHA  and  do  not  release  it  readily. 
Conversely,  astrocytes  readily  release  DHA  [45].  Astrocytes  control  the  chemical  environment 
surrounding neurons and ensure proper ion and action potential (electrical) conduction [75]. There are Nutrients 2011, 3  
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no appreciable levels of the precursors ALA or LA in brain phospholipids despite their levels in serum. 
In male rats fed a DHA-rich diet, 99% of the plasma ALA that entered the brain was diverted into 
beta-oxidation pathways, with very little (0.3%) synthesis to phospholipid DHA [76]. DHA-deficiency 
increases the proportion of ALA that is synthesized to DHA. Although polyunsaturated fatty acids 
easily cross the blood-brain barrier by diffusion only the longer-chain fatty acids are incorporated into 
brain phospholipids.  
At synaptic membranes, the liberation of AA and DHA from the phospholipids upon stimulation by 
PLA2  is  coupled  by  G-proteins  to  numerous  receptors,  such  as  cholinergic  receptors.  During 
cholinergic stimulation, for instance, AA and DHA are released from the membrane into the cytosol 
whereby small fractions of the substrates are converted into bioactive second messengers (eicosanoids 
or docosanoids) [77]. Of the remaining pool of released fatty acids, a small portion may be diverted to 
β-oxidation  pathways  but  by  far  the  largest  proportions  are  recycled  back  into  the  membrane 
phospholipids [78].  
This  constant  turnover  and  remodeling  of  membrane  phospholipid  fatty  acids  may  similarly 
influence the remodeling of other membrane structures, such as synaptic vesicles. In an interesting 
study on learning in rats fed either an n-6 (safflower oil) versus an n-3 (perilla oil) rich diet, those on 
the n-6 rich n-3 deficient diet had significantly more difficultly learning the task, an effect that was 
associated with less vesicle density in the hippocampus. The n-6 group showed little difference in 
synaptic  vesicle  density  either  with  our  without  the  learning  task,  but  the  n-3  group  significantly 
increased vesicle number and density in the hippocampal CA1 region after the learning task. This 
corresponded with increased DHA in the membrane phospholipids for the n-3 group, with much less 
DHA (almost half) in the n-6 group.  
Interestingly, the constant recycling of AA and DHA are regulated by different enzymes. Three 
different isoforms of PLA2 have so far been identified; an AA-specific form for release into the cell, 
cytosol  PLA2  (cPLA2),  an  AA-specific  secretory  form  (sPLA2),  and  a  calcium-independent  form 
(iPLA2) that is believed to be specific for DHA and is also found in astrocytes [79]. By targeting such 
fatty acid specific enzymes, drugs have differential effects on fatty acid turnover. For instance the 
mood altering drugs lithium, carbamazepine and valproate result in reductions of the rate of turnover 
of arachidonic acid, COX expression and PGE2 production but do not alter turnover rate of DHA [78].  
During normal neurotransmission, involving receptors coupled with PLA2 enzymes, DHA and AA 
are routinely released from the phospholipids and are predominantly and rapidly recycled back into the 
phospholipids. A small fraction is nonetheless lost to catabolic pathways, such as docosanoid and 
eicosanoid  production  or  beta-oxidation.  Rapoport  et  al.  [63]  recently  argued  that  as  there  is  no 
appreciable contribution by circulating ALA to brain phospholipid DHA (<1%), that the incorporation 
of plasma DHA into brain phospholipids exactly reflects the rate of DHA lost to metabolic catabolism. 
They combined neuroimaging (positron-emission tomography, or PET) with radioactive labeling of 
intravenously  administered  DHA  and  AA  to  quantify  the  rate  of  incorporation  into  human  brain 
phospholipids. The whole adult human brain was estimated to consume the equivalent of 4.6 mg/day 
of DHA and 17.8 mg/day of AA.  
This  technique  was  recently  repeated  by  Rapoport’s  group  [80]  in  14  human  volunteers  with 
consistent findings; the global rate of DHA incorporation in the human brain was the equivalent of the 
consumption of 3.8 ±  1.7 mg/day DHA. Further, they used published estimates of the total amount of Nutrients 2011, 3  
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DHA in the human brain (5 g) and the daily incorporation rate of 0.076% per day, to determine that the 
half-life of brain DHA was approximately 2.5 years in humans. This implies that a 5% reduction of 
brain DHA, for instance, may not manifest until approximately 49 days after its disappearance from 
plasma. This evidence for a long half life of brain phospholipid DHA suggests that dietary intervention 
studies with DHA on psychological or psychiatric outcomes may not be able to demonstrate the full 
effects of brain enrichment of DHA within weeks, regardless of the dosage given. However, mediation 
of psychological or psychiatric effects of DHA via peripheral pathways, such as the regulation of the 
production and secretion of proinflammatory cytokines, is possible in shorter time durations. 
While Rapoport et al. [63] estimates of global brain consumption are exceedingly interesting; they 
do not appear to have taken account of the synthesis of DHA from its precursors EPA, DPAn-3 and 
ALA in cerebral endothelial cells and astrocytes. Cerebral endothelial cells coop with astrocytes by 
taking up DHA precursors from serum and commencing elongation and desaturation. They then direct 
the molecules to neighboring astrocytes to complete the conversions to DHA for secretion and supply 
to nearby neurons [81]. Studies in culture have shown that the amount of DHA produced and secreted 
by astrocytes is dependent upon the availability of preformed DHA. When present, even in large 
amounts, there is a reduction of DHA secretion but it does not altogether cease. This indicates a 
constitutional or basal role for DHA synthesis from astrocytes, and suggests that it fulfils an essential 
function [82]. Post-mortem examination of 15 human brains of those with major depression compared 
with age matched controls found a significant reduction in the density of astrocytes located near blood 
vessels in the prefrontal cortex of those with depression [83]. Further, when the supply of DHA or its 
precursors  to  the  brain  is  inadequate  there  is  evidence  of  damage  to  astrocytes  and  neuronal 
shrinkage [84].  
Brain phospholipid uptake of DHA depends upon serum levels of DHA and its precursors, which 
depend  upon  both  dietary  intake  and  liver  biosynthesis.  Dietary  supplementation  with  DHA 
substantially influences brain DHA content [72]. In a study on brain uptake of DHA and AA from 
different dietary groups of baboons, there was little effect of treatment for AA, but brain DHA was 
sensitive to dietary manipulations. Baboons were randomized into groups of DHA enriched formula 
(0.3%  energy  DHA  and  0.6%  energy  AA)  in  similar  proportions  to  that  used  in  human  infant  
formula. The post-mortem brains were compared with those of breastfed baboons, the ―gold standard‖ 
(0.68 ±  0.22% energy DHA, 0.62 ±  0.22% energy AA) at 4 weeks of age. The DHA supplemented 
formula  group  was  able  to  supply  DHA  to  all  brain  regions  comparable  with  those  of  breastfed 
baboons with two notable exceptions. DHA supplemented formula did not adequately supply cerebral 
cortex or cerebellum phospholipids with DHA to levels comparable with those of breastfed baboons. 
Diau et al. [72] speculated that this may be due to the aggressive growth of these large cortical regions 
during the first few weeks of life coupled with the fact that breast milk also contains EPA and DPAn-3 
(0.84  ±   0.16%  energy  in  breast  milk  versus  0.1%  energy  in  formula),  which  are  more  efficient 
precursors for brain DHA than ALA, which is traditionally used in infant formula.  
6. Neurodevelopment 
The cerebral cortex of ten infants that had died of cot death were examined and correlated with their 
diet. The five infants fed on breast milk had significantly (p = 0.02) higher proportion of DHA (9.7%) Nutrients 2011, 3  
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in the phospholipids of the cerebral cortex than the five formula fed matched controls (7.6%) [85]. 
In further  research  on  35  autopsied  infants,  the  length  of  breast  feeding  was  proportional  to  the 
concentration of cortex DHA [86].  
In a single-blinded, randomized, controlled trial of DHA in infant formula, infants were randomized 
to receive DHA versus no-DHA supplemented formula if the mothers had elected to bottle feed from 
birth, but a group of breast-fed infants were included as a reference group. It was noted that mothers 
that chose to breast feed had attained a higher level of education than those who opted to formula feed, 
a potential confounding variable in that those babies may be more intelligent due to hereditary or 
social status related influences. Nonetheless, of the 79 infants that completed the study, those that were 
breast fed and those that had the DHA formula had significantly higher visual evoked potential (VEP) 
acuity  at  both  16  weeks  (p  <  0.001)  and  30  weeks  (p  <  0.01)  than  the  no-DHA  formula  feed 
infants [87]. Further, erythrocyte phospholipid DHA was the only fatty acid which was correlated with 
VEP in all infant groups at both measurement times. Makrides et al. [87] concluded that DHA is an 
essential nutrient for normal neural and visual development.  
There remains an independent effect for breast milk on intelligence even after the level of mother’s 
education and social status is statistically controlled. In 300 children in the UK on an abbreviated 
Weschler Intelligence Scale for Children, those that had received breast feeding in the weeks following 
birth had higher scores at age 7.5–8 years of age. After adjusting for mother’s education and social 
class, breast feeding predicted an 8.3 point advantage on the test over those that were formula fed from 
birth (p < 0.0001) [88].  
The evidence is strong for a causal relationship between cerebral DHA phospholipids and visual 
and neurodevelopment [89,90]. Dietary induced changes in retinal DHA phospholipids have also been 
associated with changes in retinal function. However, some studies have shown no differences between 
formula fed and breast fed infants in visual and cognitive tests [91]. The inconsistencies could be 
related to confounding variables such as smoking, illness, infection, sex, age, gestational age, birth 
weight,  alcohol  and/or  strenuous  exercise  during  pregnancy,  nutrition,  marital  status  and  bilirubin 
levels in the first week of life [92].  
The studies by Birch and Hoffman et al. [93] conclusively demonstrated the essentiality of DHA for 
infant visual acuity development. In 108 healthy term infants, 79 were randomized into one of three 
diet groups, all exclusively formula-fed from birth, and a group of 29 exclusively breast-fed for at least 
17 weeks. Infants that were randomized were allocated a diet groups consisting of formula that was  
(i) not supplemented with DHA or AA, or (ii) contained DHA (0.35% of total fatty acids) but no AA, 
or (iii) contained DHA (0.36%) and AA (0.72%). At 17 weeks, the completion of the randomized 
feeding period, those in the non-supplemented formula group had significantly lower DHA than those 
in the other three groups (all p ≤ 0.0025). After 52 weeks, DHA and n-3/n-6 ratio predicted statistically 
higher  sweep  VEP  acuity.  Thus  there  is  no  longer  any  question  of  the  essentiality  of  DHA  in  
infant nutrition. 
One issue that requires further investigation is the determination of the precise amount of dietary 
DHA required for optimum growth and development. Researchers often use the levels of DHA in 
breast milk as the yardstick. However, over the second half of the last century, much of the DHA has 
been processed out of the food supply [94]. Most Western women are themselves at risk of DHA 
insufficiency [95]. Stable isotope research has demonstrated that the 30% of breast milk longer-chain Nutrients 2011, 3  
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polyunsaturated fatty acids is directly sourced from the maternal diet, where 70% comes from maternal 
stores, such as adipose tissue and endogenous synthesis [96]. When maternal stores are low and this is 
combined with a low-fat/high carbohydrate diet, increased endogenous fatty acid synthesis occurs in 
the mammary glands [96]. Trans fatty acids, such as those found in many processed manufactured 
foods, are rapidly incorporated into breast milk and are associated with adverse effects in infants and 
children [97]. 
Another  contemporary  issue  of  importance  to  Western  women  and  public  health  bodies  is  the 
potential  risk  of  exposure  to  contaminants,  such  as  methyl-mercury,  from  agricultural  run-offs  in 
coastal seafood and the harm this may have on neurodevelopment. These concerns are reflected by 
public health advice to limit seafood consumption during pregnancy. In the US it is recommended to 
limit  seafood  consumption  to  340  g  per  week  during  pregnancy.  However,  Hibbeln  et  al.  [98] 
conducted  a  powerful  observational  cohort  study  of  over  11,875  children.  After  adjustment  for 
28 potential  confounding  variables,  consumption  of  less  than  340  g  per  week  of  seafood  was 
independently associated with the child being in the lowest quartile for verbal intelligence quotient 
compared with mothers that had consumed over 340 g per week seafood.  
Low seafood intake was also associated with lower development on a range of outcomes relating to 
social behavior, communication and fine motor skills. Hibbeln et al. [98] concluded that the risks of 
the loss of nutrients from the diet by far outweighed the risk of contamination from trace elements. In 
another study, Hibbeln et al. [99] estimated that 900 mg per day of EPA + DHA from seafood during 
pregnancy would be adequate to provide for the neurodevelopment requirements of the fetus and the 
prevention of maternal depression in the mother. 
Cohort  studies  have  demonstrated  the  long-term  impact  of  the  deficiency  of  DHA  from  infant 
formula.  DHA  status  at  birth  was  correlated  with  problem  internalizing  behaviors  in  393  Dutch 
children at 7 years, an observation that was not present in breast fed infants [100]. Animal studies have 
demonstrated that DHA deficiency during gestation and soon after birth could not be fully corrected 
later in life. At 33 weeks, the hypothalamus glycerophospholipids of young pups had significantly 
reduced DHA compared with controls (that had received ALA for 3 weeks after birth) even after 
dietary  correction  with  ALA  for  30  weeks.  It  appeared  that  the  early  deficiency  of  ALA  had 
irreversibly down-regulated the converting enzyme delta-6 desaturase [101].  
7. Modern Western Diet  
Humans have evolved consuming approximately equal amounts of dietary DHA and AA [102]. 
Over the past century this balance has been dramatically shifted in favor of the omega-6 fatty acids. 
The agricultural and industrial revolutions and inventions such as that of the seed drill have led to a 
dramatic increase in the availability of the fatty acids from seed oil, rich in the omega-6 fatty acid, 
linoleic acid [103]. The domestication of livestock and poultry, resulted in a shift in livestock feed 
from an n-3 rich plant based diet to an n-6 rich seed based diet. For instance, arachidonic acid is the 
predominate polyunsaturated fatty acid found in the meat of Western cultures, where DHA and AA are 
represented  about  equally  in  the  meat  of  free-range  wild  animals  such  as  the  meat  source  of  the 
Paleolithic diet today [104]. Nutrients 2011, 3  
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During the 1960s the epidemic in coronary heart disease was attributed to the increased consumption 
of saturated fatty acids. Public health campaigns in Western countries such as the US and Australia 
urged the public to reduce fats and to replace saturated fatty acids with polyunsaturated fatty acids. 
Trans fats were freely introduced into the food supply in processed manufactured products, such as 
margarines, in many Western countries. However, it was not until much later that the research could 
capture the data associating the detrimental effects of these fats on health [105,106]. A recent review 
found that a comprehensive strategy to limit the use of trans fats globally would likely ―prevent tens of 
thousands of CHD events worldwide each year‖ [107]. Increased intake of saturated fats and trans 
fatty acids not only displaces intake of dietary essential fatty acids, but blocks their biosynthesis [108]. 
Because the n-3 and n-6 fatty acids compete with each other for the same enzymes, notably delta-6 
desaturase,  an  excess  of  omega-6  dominates  the  enzyme,  further  inhibiting  the  synthesis  of  the  
omega-3 fatty acids [102,109].  
In evolutionary terms the last century is an incredibly short period of time. During this time a 
dramatic shift in our intake of dietary fat corresponds with the rise of Western so-called ―life-style‖ 
diseases, particularly heart disease but latterly neurological disorders. The underlying factor for the 
increases in the incidences of these diseases may be attributable to an inadequate proportion of DHA in 
membrane phospholipids, driven largely by excessive consumption of omega-6 fatty acids.  
8. Future Directions 
There has been much interest in DHA in recent years, particularly with regards to a promising role 
for  the  nutrient  in  neurodevelopment,  neurocognition  and  neurodegenerative  disorders.  There  is 
promising emerging research into a role for DHA in the prevention of neuropsychiatric disorders such 
as psychosis [110] and affective disorders [111]. Perhaps the most cutting edge body of emerging work 
is examining a role for DHA in the facilitation of adaptation during stress [112–119]. A workshop was 
convened last year entitled ―Nutritional Armor for the Warfighter: Can Omega-3 Fatty Acids Enhance 
Stress Resilience, Wellness, and Military Performance?‖ to provide the US Department of Defense 
with on overview of the science behind omega-3 fatty supplementation [120]. The recognition that 
omega-3 fatty acids, particularly DHA, may improve resilience for soldiers echoes the observations 
made of the early humans that the discovery of seafood may have helped to increase resilience to 
natural pressures. A possible role for DHA in adaptation and resilience is an exceedingly interesting 
line of investigation.  
Driven by consumer demand, and despite additional production costs, modern food processors are 
increasingly fortifying manufactured food products, particularly milk, bread and eggs with DHA from 
algae and fish oil [121]. Algal-DHA is being fed to domestic animals to enrich the polyunsaturated 
portion of red meat and eggs [122]. Novel GM oilseeds are also being researched for supplementation 
to domestic animal feed [123]. A review of intervention studies of milk supplemented with fish oil 
demonstrates that consumption of DHA-enriched milk was associated with beneficial health effects 
comparable  with  direct  fish  consumption,  such  as  the  reduction  of  LDL  cholesterol  and  serum 
triglycerides [124].  
The meat and eggs from pasture-fed animals contain significantly higher proportions of EPA and 
DHA than those from farm intensive methods that incorporate seed feeding practices, rich in LA. Nutrients 2011, 3  
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Animal feed supplemented with grain, such as for chicken food and as found in the extensive use of 
feedlots for beef accelerate the loss of DHA from the diet and subsequently from phospholipids [125–127]. 
Furthermore, meat from wild animals contains significantly higher DHA than meat from domesticated 
animals, be they ―free-range‖, pasture-fed, and/or organically-reared animals [125]. Crawford et al. [125] 
present data on a range of meat samples, including organic and wild game, and demonstrate a dramatic 
and consistent loss of EPA and DHA from domesticated meat. These differences are most extreme for 
DHA. In domesticated conventionally-reared and organic beef, there were only trace levels of DHA  
(<0.1% of total fatty acids) but DHA was present in venison (0.7%) and buffalo (0.9%).  
Modern humans have adapted to a dietary intake of preformed DHA. The displacement of DHA 
from the diet has been driven by an excessive over-consumption of omega-6 fatty acids, which has 
resulted in the gradual depletion of DHA from membrane phospholipids. This process characterizes 
the Western diet over the past century, the time-line which corresponds with the rise of ―modern 
lifestyle diseases‖. There is strong evidence for the benefits of DHA supplementation in the prevention 
of  primary  and  secondary  heart  disease  and  promising  evidence  is  emerging  for  its  benefits  in 
neurological and neuropsychiatric disorders. There is an urgent imperative to continue this research in 
light of findings that brain disorders have become the leading cost of the burden of ill-health in the  
25-member states of the European Union [125]. 
DHA is a unique nutrient that should be regularly consumed as oily fish or supplemented as fish oil 
or algal supplements. In addition, a diet consisting of pasture-fed livestock and poultry will provide 
meat and eggs with higher proportions of DHA. Fortified bread and milk will also provide higher 
levels of DHA. It appears that Western consumers and health bodies alike are becoming increasingly 
aware of the potential benefits offered by reinstating this ancient nutrient as a nutritional staple for the 
optimization of physical and mental health and wellbeing.  
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